The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
Titel:
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
Auteur:
Müller-Ladner, Ulf Dignass, Axel Gaffney, Karl Jadon, Deepak Matucci-Cerinic, Marco Lobaton, Triana Carron, Philippe Gisbert, Javier P. Pande, Ira Utzinger, Maximilian Addison, Janet